**
As the United States grapples with a significant cyclosporiasis outbreak, recent data suggests that the number of infections linked to the single-celled parasite may be on the decline. With over 18,000 suspected and confirmed cases reported by late July—marking the largest outbreak on record—public health officials are cautiously optimistic yet remain vigilant about potential ongoing risks.
Insights from Testing Data
John Osiecki, vice-president of medical affairs at bioMerieux, a French company renowned for its diagnostic testing, expressed hope that the outbreak may be diminishing. He noted that their analysis, featured in the Syndromic Trends report, indicates a drop in positivity rates for tests related to gastrointestinal illnesses. However, he cautioned that this decline could be influenced by an increase in testing frequency, as heightened public awareness encourages more individuals to seek tests.
“I’m feeling confident we’re heading in that direction, but we need to continue to monitor this as we go forward,” Osiecki explained. While the data shows a promising trend, the surge in testing could lead to lower positivity rates even if the outbreak persists.
The Role of Public Awareness
The potential impact of public awareness cannot be overlooked. Osiecki noted that conversations in social settings reflect a growing concern among consumers, with many opting to avoid iceberg lettuce—identified as a source of the outbreak—as a precaution. This heightened vigilance could be contributing to the apparent decline in case positivity.
Conversely, data from the Centers for Disease Control and Prevention (CDC) presents a different timeline and carries a high level of reliability. The CDC has confirmed 6,707 cases of cyclosporiasis in the U.S. and is currently analysing additional information to validate 11,500 other suspected cases.
Fluctuations in Infection Rates
According to bioMerieux, the positivity rate for illnesses involving parasites peaked at 15.6% in mid-July. This spike is notably higher than the same period in 2025, which recorded a 2.9% positivity rate. Importantly, the increase in cases during the summer months is a known trend, but this year’s peak stands out as an anomaly compared to previous years.
However, caution is warranted when interpreting these findings. The bioMerieux panel tests for multiple parasites, not exclusively cyclospora. Additionally, Medicare—a major U.S. insurer—only covers the testing for individuals who are immunosuppressed, and the cost of the test is $417, which may limit access for some patients.
Ongoing Investigations and Concerns
Despite the signs of a potential decline, food safety researchers have raised concerns that the outbreak may be more extensive than currently acknowledged. The Food and Drug Administration (FDA) is actively investigating multiple outbreaks of cyclosporiasis that remain without identified sources. Notably, lettuce linked to the outbreak has been distributed across 27 states.
Recent reports from New Hampshire highlight the ongoing risks, as cases of individuals falling ill after consuming Taylor Farms’ lettuce from Mexico were confirmed in mid-July. These incidents occurred outside of the current outbreak designation, underscoring the need for continued monitoring and public health awareness.
Why it Matters
The implications of this cyclosporiasis outbreak extend beyond immediate health risks. With thousands of cases under investigation and the potential for further spread, it is crucial for both health authorities and the public to remain alert. The response to this outbreak highlights the importance of food safety measures and public education in preventing future incidents. As communities navigate this health challenge, the need for vigilance and informed decision-making is paramount to protect individuals and ensure public health.
